The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
STELLAR-303: A phase 3 study of XL092 in combination with atezolizumab versus regorafenib in patients with previously treated metastatic colorectal cancer (mCRC).
 
J. Randolph Hecht
Stock and Other Ownership Interests - Actym Therapeutics; Rafael Pharmaceuticals
Consulting or Advisory Role - Astellas Pharma; Corcept Therapeutics; Exelixis; Gilead Sciences; Gritstone Bio; Istari; Notch Therapeutics; Regenacy Pharmaceuticals; Tempus
Research Funding - Amgen (Inst); ARMO BioSciences (Inst); Astellas Pharma (Inst); Bold Therapeutics (Inst); Gritstone Bio (Inst); Lilly (Inst); Merck (Inst); Tesaro/GSK (Inst); Tizona Therapeutics, Inc. (Inst)
Travel, Accommodations, Expenses - Amgen
 
Josep Tabernero
Stock and Other Ownership Interests - Oniria Therapeutics
Consulting or Advisory Role - Array BioPharma; AstraZeneca; Bayer; Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo; F. Hoffmann LaRoche; Genentech; HalioDx; Hutchison MediPharma; Ikena Oncology; Inspirna; IQvia; Lilly; Menarini; Merck Serono; Merus; Mirati Therapeutics; MSD; Neophore; Novartis; Ona Therapeutics; Orion Biotechnology; Peptomyc; Pfizer; Pierre Fabre; Samsung Bioepis; Sanofi; Scandion Oncology; Scorpion Therapeutics; Seagen; Servier; Sotio; Taiho Pharmaceutical; Tessa Therapeutics; TheraMyc
Other Relationship - Imedex/HMP; Medscape; MJH Life Sciences; Peerview; Physicans' Education Resource
 
Aparna Raj Parikh
Consulting or Advisory Role - Abbvie; Bayer; Biofidelity; Checkmate Pharmaceuticals; CVS; Delcath Systems; Delcath Systems; Foundation Medicine; Genconn Biotech; Genconn Biotech; Guardant Health; Illumina; Inivata; Lilly; Natera; Pfizer; Roche/Genentech; SAGA Diagnostics; Scarce; Seagen; Taiho Oncology; UpToDate; Value Analytics Labs; xCures; xCures
Research Funding - Array BioPharma (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); Erasca, Inc; Genentech (Inst); Guardant Health (Inst); Lilly (Inst); Mirati Therapeutics (Inst); Novartis Pharmaceuticals UK Ltd. (Inst); Plexxikon (Inst); PMV Pharma; PureTech (Inst)
Other Relationship - C2i genomics; Parithera; Xact Robotics
 
Yijia Wang
Employment - Exelixis
Stock and Other Ownership Interests - Exelixis
 
Zhong Wang
Employment - Exelixis
Stock and Other Ownership Interests - Exelixis
 
Martin Schwickart
Employment - Exelixis
Stock and Other Ownership Interests - Exelixis
 
Dominic Curran
Employment - Exelixis
Stock and Other Ownership Interests - Exelixis
 
Anwaar Saeed
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo/Astra Zeneca; Exelixis; Five Prime Therapeutics; Pfizer
Research Funding - Actuate Therapeutics (Inst); Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Daiichi Sankyo/UCB Japan (Inst); Exelixis (Inst); Five Prime Therapeutics (Inst); innovent biologics (Inst); KAHR Medical (Inst); Merck Sharp & Dohme (Inst); Seagen (Inst)